Home » Pipeline
Pipeline
| Company | Drug/Device | Medical Condition | Status |
|---|---|---|---|
| COVID-19 Trials | |||
| Lattice Biologics | AmnioBoost | severe acute respiratory syndrome (SARS) related to COVID-19 infection | initiation of phase 1 trial |
| Moderna, Inc. | mRNA vaccine (mRNA-1273) | coronavirus (SARS-CoV-2/COVID-19) | first patient dosed in phase 1 trial |
| Regeneron Sanofi |
Kevzara (sarilumab) | patients hospitalized with severe COVID-19 infection | initiation of phase 2/3 trial |
| Genentech | Actemra (tocilizumab) plus standard of care | hospitalized adults with severe COVID-19 pneumonia | initiation of phase 3 trial |
| Roche | cobas SARS-CoV-2 Test | coronavirus (SARS-CoV-2/COVID-19) | approved by the FDA |
| All Other Trials | |||
| Surface Oncology | SRF617 | advanced solid tumors | initiation of phase 1/1b trial |
| Arch Biopartners | Metablok (LSALT peptide) | inflammation in the lungs, liver and kidneys | patient dosing complete in phase 1 trial |
| InxMed | IN10018 monotherapy and in combination with MEKi | metastatic uveal melanoma or NRAS mutant metastatic melanoma | first patient dosed in phase 1b trial |
| Applied Genetic Technologies Corporation | adeno-associated virus (AAV)-based gene therapy | achromatopsia due to mutation in the ACHM CNGB3 or ACHM CNGA3 genes | patient enrollment complete in adult dose group in phase 1/2 trial |
| Cellphire | Thrombosomes | bleeding patients with thrombocytopenia | initiation of phase 2 trial |
| BELLUS Health | BLU-5937 | refractory chronic cough | patient enrollment complete in phase 2 trial |
| Graybug Vision | GB-102 | anti-VEGF-responsive wet age-related macular degeneration | patient enrollment complete in phase 2b trial |
| Abeona Therapeutics | EB-101 gene therapy | recessive dystrophic epidermolysis bullosa | first patient dosed in phase 3 trial |
| Blue Earth Diagnostics | rhPSMA-7.3 (18F), Prostate Specific Membrane Antigen-targeted radiohybrid PET imaging agent | newly diagnosed prostate cancer | first patient dosed in phase 3 trial |
| Alpine Immune Sciences | ALPN-101 | prevention and treatment of acute GVHD | Orphan Drug designation granted by the FDA |
| Rhythm Pharmaceuticals | setmelanotide | Alström syndrome | Orphan Drug designation granted by the FDA |
| Eli Lilly Incyte |
Olumiant (baricitinib) | alopecia areata | Breakthrough Therapy designation granted by the FDA |
| Neural Fiber Optic Systems | FLOXsp Spinal Cord Flow and Oxygenation System | blood flow and oxygenation monitoring of the spinal cord to prevent paralysis during and after aortic and major spine surgery | Breakthrough Device designation granted by the FDA |
| Endologix | Alto Abdominal Stent Graft System | abdominal aortic aneurysms | approved by the FDA |
